Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- COLLABORATIVE DRUG DISCOVERY, INC.
- Proposal award date
- 2018-08-01
- Contract end date
- 2019-05-31
- UEI
- KC1DAXHM8424
- Solicitation number
- PA17-302
- Topic code
- 100
Research abstract
PROJECT SUMMARY
Collaborative Drug DiscoveryIncCDDproposes to develop a novel approach based on deep learning neural
networks to encode molecules into chemically rich vectorsWe will first apply this representation to build
more powerful computational models that can more accurately predict properties such as bioactivityADMEToxand pharmacokinetics across libraries of molecular structuresThe ultimate goal is to leverage this representation to generate novel compounds with better combinations of propertiesBoth of these capabilities will
help scientists to accelerate discovery of new drugs broadly across many therapeutic areasScientists engaged in drug discovery research from academic laboratories to large pharmaceutical
companies rely on computational QSAR models to predict pharmacologically relevant properties and obviate
the need to perform expensivetime consuming assaysmany of which require animal studiesfor every
molecule of interestSome propertiese glogPcan now be modeled with such high confidence that the
models have replaced the need to perform the assaysbut many other critical propertiese gsolubilityADMEPKhERGremain far from this goalWe expect that our proposed chemically rich vectors will significantly
advance the state of the art beyond what can be achieved with conventional descriptors and fingerprintsImproved models will enable researchers to select lead candidate series more effectivelyexplore chemical
space around leads to generate novel IP more efficientlyreduce failure rates for compounds advancing
through the drug discovery pipelineand accelerate the entire drug discovery processThese benefits will be
realized broadly across most therapeutic areasOur central innovation is a novel computational strategyfirst develop a deep learningDLmodel
optimized to best capture the essential structural and chemical features of moleculesstarting from the most
natural structural representationthen validate the DL model by applying it to improve QSAR modeling of
pharmacological propertiesand finally extend it to generate previously unknown molecules that have superior
propertiesthe so calledinverse QSARproblemwhich is the Holy Grail of computational medicinal
chemistryOthers have unsuccessfully tried to leap directly to solve the inverse QSAR problemWe propose a
more patient and methodical approach that will allow the neural network to perform self supervised training to
learn about chemical structures and properties from readily availableextremely large datasetsthen transfer
this learning to improve modelingonly after establishing this solid foundation do we intend to apply the
models to attempt inverse QSARPrior attempts in this area have also relied on neural network architectures
designed originally for language processingWe will design a new architecturemore akin to neural network
architectures that have proven most successful at image classificationand optimize it to directly process themolecular graphthat represents the relationship of atoms and bonds in molecules PROJECT NARRATIVE
The proposed project will create novel computational tools that will help researchers to understand whether
potential new drugs are likely to be both safe and effectiveand identify similar compounds that are likely to be
safer and more effective against the same targetThis innovative capability will help to accelerate the discovery
and development of novel and improved drugs against a wide range of diseases!
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
17 SBIR/STTR records share this UEI (2010–2022). Reported award amounts total $14,412,575. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: Department of Health and Human Services
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards